A type I cAMP-dependent protein kinase regulatory subunit that plays a role in confering CYCLIC AMP activation of protein kinase activity. It has a lower affinity for cAMP than the CYCLIC-AMP-DEPENDENT PROTEIN KINASE RIBETA SUBUNIT.
A group of enzymes that are dependent on CYCLIC AMP and catalyze the phosphorylation of SERINE or THREONINE residues on proteins. Included under this category are two cyclic-AMP-dependent protein kinase subtypes, each of which is defined by its subunit composition.
An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH.
A family of enzymes that catalyze the conversion of ATP and a protein to ADP and a phosphoprotein.
An serine-threonine protein kinase that requires the presence of physiological concentrations of CALCIUM and membrane PHOSPHOLIPIDS. The additional presence of DIACYLGLYCEROLS markedly increases its sensitivity to both calcium and phospholipids. The sensitivity of the enzyme can also be increased by PHORBOL ESTERS and it is believed that protein kinase C is the receptor protein of tumor-promoting phorbol esters.
The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety.
A CALMODULIN-dependent enzyme that catalyzes the phosphorylation of proteins. This enzyme is also sometimes dependent on CALCIUM. A wide range of proteins can act as acceptor, including VIMENTIN; SYNAPSINS; GLYCOGEN SYNTHASE; MYOSIN LIGHT CHAINS; and the MICROTUBULE-ASSOCIATED PROTEINS. (From Enzyme Nomenclature, 1992, p277)
Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme.
Agents that inhibit PROTEIN KINASES.
A multifunctional calcium-calmodulin-dependent protein kinase subtype that occurs as an oligomeric protein comprised of twelve subunits. It differs from other enzyme subtypes in that it lacks a phosphorylatable activation domain that can respond to CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE KINASE.
A monomeric calcium-calmodulin-dependent protein kinase subtype that is expressed in a broad variety of mammalian cell types. Its expression is regulated by the action of CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE KINASE. Several isoforms of this enzyme subtype are encoded by distinct genes.
A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.
A cyclic AMP-dependent protein kinase subtype primarily found in particulate subcellular fractions. They are tetrameric proteins that contain two catalytic subunits and two type II-specific regulatory subunits.
A group of enzymes that catalyzes the phosphorylation of serine or threonine residues in proteins, with ATP or other nucleotides as phosphate donors.
A group of cyclic GMP-dependent enzymes that catalyze the phosphorylation of SERINE or THREONINE residues of proteins.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
The rate dynamics in chemical or physical systems.
A heat-stable, low-molecular-weight activator protein found mainly in the brain and heart. The binding of calcium ions to this protein allows this protein to bind to cyclic nucleotide phosphodiesterases and to adenyl cyclase with subsequent activation. Thereby this protein modulates cyclic AMP and cyclic GMP levels.
Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics.
A superfamily of PROTEIN-SERINE-THREONINE KINASES that are activated by diverse stimuli via protein kinase cascades. They are the final components of the cascades, activated by phosphorylation by MITOGEN-ACTIVATED PROTEIN KINASE KINASES, which in turn are activated by mitogen-activated protein kinase kinase kinases (MAP KINASE KINASE KINASES).
Established cell cultures that have the potential to propagate indefinitely.
A species of ciliate protozoa. It is used in biomedical research.
An intracellular signaling system involving the MAP kinase cascades (three-membered protein kinase cascades). Various upstream activators, which act in response to extracellular stimuli, trigger the cascades by activating the first member of a cascade, MAP KINASE KINASE KINASES; (MAPKKKs). Activated MAPKKKs phosphorylate MITOGEN-ACTIVATED PROTEIN KINASE KINASES which in turn phosphorylate the MITOGEN-ACTIVATED PROTEIN KINASES; (MAPKs). The MAPKs then act on various downstream targets to affect gene expression. In mammals, there are several distinct MAP kinase pathways including the ERK (extracellular signal-regulated kinase) pathway, the SAPK/JNK (stress-activated protein kinase/c-jun kinase) pathway, and the p38 kinase pathway. There is some sharing of components among the pathways depending on which stimulus originates activation of the cascade.
Phosphotransferases that catalyzes the conversion of 1-phosphatidylinositol to 1-phosphatidylinositol 3-phosphate. Many members of this enzyme class are involved in RECEPTOR MEDIATED SIGNAL TRANSDUCTION and regulation of vesicular transport with the cell. Phosphatidylinositol 3-Kinases have been classified both according to their substrate specificity and their mode of action within the cell.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
A mitogen-activated protein kinase subfamily that regulates a variety of cellular processes including CELL GROWTH PROCESSES; CELL DIFFERENTIATION; APOPTOSIS; and cellular responses to INFLAMMATION. The P38 MAP kinases are regulated by CYTOKINE RECEPTORS and can be activated in response to bacterial pathogens.
The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
A dsRNA-activated cAMP-independent protein serine/threonine kinase that is induced by interferon. In the presence of dsRNA and ATP, the kinase autophosphorylates on several serine and threonine residues. The phosphorylated enzyme catalyzes the phosphorylation of the alpha subunit of EUKARYOTIC INITIATION FACTOR-2, leading to the inhibition of protein synthesis.
Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed)
A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
A cytoplasmic serine threonine kinase involved in regulating CELL DIFFERENTIATION and CELLULAR PROLIFERATION. Overexpression of this enzyme has been shown to promote PHOSPHORYLATION of BCL-2 PROTO-ONCOGENE PROTEINS and chemoresistance in human acute leukemia cells.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts.

Increased expression of the RIalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer. (1/164)

The primary element in the cAMP signal transduction pathway is the cAMP-dependent protein kinase (PKA). Expression of the RIalpha subunit of type I PKA is elevated in a variety of human tumours and cancer cell lines. The purpose of this study was to assess the prognostic importance of RIalpha expression in patients with ovarian cancer. We have evaluated the expression of RIalpha in a panel of human ovarian tumours (n = 40) and five human ovarian cancer cell lines using quantitative reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis. The human ovarian cell lines OAW42 and OTN14 express high endogenous levels of RIalpha mRNA and protein (at significantly higher mRNA levels than high tissue expressors, P < 0.05). The ovarian cell line A2780 expresses low endogenous levels of RIalpha mRNA and protein (also at higher mRNA levels than low tissue expressors, P < 0.05). Quantitative RT-PCR revealed no significant difference in RIalpha mRNA expression between different ovarian histological subtypes in this study. No associations were found between RIalpha mRNA expression and differentiation state. RIalpha mRNA expression was significantly associated with tumour stage (P = 0.0036), and this remained significant in univariate analysis (P = 0.0002). A trend emerged between RIalpha mRNA expression levels and overall survival in univariate analysis (P = 0.051), however, by multivariate analysis, stage remained the major determinant of overall survival (P = 0.0001). This study indicates that in ovarian epithelial tumours high RIalpha mRNA expression is associated with advanced stage disease. RIalpha expression may be of predictive value in ovarian cancer and may be associated with dysfunctional signalling pathways in this cancer type.  (+info)

Diminished levels of protein kinase A RI alpha and RI beta transcripts and proteins in systemic lupus erythematosus T lymphocytes. (2/164)

Deficient type I protein kinase A phosphotransferase activity occurs in the T cells of 80% of subjects with systemic lupus erythematosus (SLE). To investigate the mechanism of this deficient isozyme activity, we hypothesized that reduced amounts of type I regulatory (RI) isoform transcripts, RIalpha and RIbeta, may be associated with a diminution of RIalpha and/or RIbeta protein. Sixteen SLE subjects with a mean (+/-1 SD) SLE disease activity index of 12.4 +/- 7.2 were studied. Controls included 16 normal subjects, six subjects with primary Sjogren's syndrome (SS), and three subjects with SS/SLE overlap. RT-PCR revealed that normal, SS, SS/SLE, and SLE T cells expressed mRNAs for all seven R and catalytic (C) subunit isoforms. Quantification of mRNAs by competitive PCR revealed that the ratio of RIalpha mRNA to RIbeta mRNA in normal T cells was 3.4:1. In SLE T cells there were 20 and 49% decreases in RIalpha and RIbeta mRNAs (RIbeta; p = 0.008), respectively, resulting in an RIalpha:RIbeta mRNA of 5.3:1. SS/SLE T cells showed a 72.5% decrease in RIbeta mRNA compared with normal controls (p = 0.01). Immunoblotting of normal T cell RIalpha and RIbeta proteins revealed a ratio of RIalpha:RIbeta of 3.2:1. In SLE T cells, there was a 30% decrease in RIalpha protein (p = 0.002) and a 65% decrease in RIbeta protein (p < 0.001), shifting the ratio of RIalpha:RIbeta protein to 6.5:1. T cells from 25% of SLE subjects lacked any detectable RIbeta protein. Analysis of several lupus T cell lines demonstrated a persistent deficiency of both proteins, excluding a potential effect of disease activity. In conclusion, reduced expression of RIalpha and RIbeta transcripts is associated with a decrement in RIalpha and RIbeta proteins and may contribute to deficient type I protein kinase A isozyme activity in SLE T cells.  (+info)

Structural characterization of the membrane-associated regulatory subunit of type I cAMP-dependent protein kinase by mass spectrometry: identification of Ser81 as the in vivo phosphorylation site of RIalpha. (3/164)

The mechanism by which the type Ialpha regulatory subunit (RIalpha) of cAMP-dependent protein kinase is localized to cell membranes is unknown. To determine if structural modification of RIalpha is important for membrane association, both beef skeletal muscle cytosolic RI and beef heart membrane-associated RI were characterized by electrospray ionization mass spectrometry. Total sequence coverage was 98% for both the membrane-associated and cytosolic forms of RI after digestion with AspN protease or trypsin. Sequence data indicated that membrane-associated and cytosolic forms of RI were the same RIalpha gene product. A single RIalpha phosphorylation site was identified at Ser81 located near the autoinhibitory domain of both membrane-associated and cytosolic RIalpha. Because both R subunit preparations were 30-40% phosphorylated, this post-translational modification could not be responsible for the membrane compartmentation of the majority of RIalpha. Mass spectrometry also indicated that membrane-associated RIalpha had a higher extent of disulfide bond formation in the amino-terminal dimerization domain. No other structural differences between cytosolic and membrane-associated RIalpha were detected. Consistent with these data, masses of the intact proteins were identical by LCQ mass spectrometry. Lack of detectable structural differences between membrane-associated and cytosolic RIalpha strongly suggests an interaction between RIalpha and anchoring proteins or membrane lipids as more likely mechanisms for explaining RIalpha membrane association in the heart.  (+info)

Protein kinase A-Ialpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway. (4/164)

Expression of the RIalpha subunit of cAMP-dependent protein kinase type I is increased in human cancers in which an autocrine pathway for epidermal growth factor-related growth factors is activated. We have investigated the effect of sequence-specific inhibition of RIalpha gene expression on ovarian cancer cell growth. We report that RIalpha antisense treatment results in a reduction in RIalpha expression and protein kinase A type I, and inhibition of cell growth. The growth inhibition was accompanied by changes in cell morphology and appearance of apoptotic nuclei. In addition, EGF receptor, c-erbB-2 and c-erbB-3 levels were reduced, and the basal and EGF-stimulated mitogen-activated protein kinase activities were reduced. Protein kinase A type I and EGF receptor levels were also reduced in cells overexpressing EGF receptor antisense cDNA. These results suggest that the antisense depletion of RIalpha leads to blockade of both the serine-threonine kinase and the tyrosine kinase signaling pathways resulting in arrest of ovarian cancer cell growth.  (+info)

Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. (5/164)

Overexpression of the RIalpha subunit of cAMP-dependent protein kinase (PKA) has been demonstrated in various human cancers. PKA has been suggested as a potential target for cancer therapy. The goal of the present study was to evaluate an anti-PKA antisense oligonucleotide (mixed-backbone oligonucleotide) as a therapeutic approach to human cancer treatment. The identified oligonucleotide inhibited the growth of cell lines of human colon cancer (LS174T, DLD-1), leukemia (HL-60), breast cancer (MCF-7, MDA-MB-468), and lung cancer (A549) in a time-, concentration-, and sequence-dependent manner. In a dose-dependent manner, the oligonucleotide displayed in vivo antitumor activity in severe combined immunodeficient and nude mice bearing xenografts of human cancers of the colon (LS174T), breast (MDA-MB-468), and lung (A549). The routes of drug administration were intraperitoneal and oral. Synergistic effects were found when the antisense oligonucleotide was used in combination with the cancer chemotherapeutic agent cisplatin. The pharmacokinetics of the oligonucleotide after oral administration of (35)S-labeled oligonucleotide into tumor-bearing mice indicated an accumulation and retention of the oligonucleotide in tumor tissue. This study further provides a basis for clinical studies of the antisense oligonucleotide targeted to the RIalpha subunit of PKA (GEM 231) as a cancer therapeutic agent used alone or in combination with conventional chemotherapy.  (+info)

A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors. (6/164)

GEM231 is a mixed-backbone oligonucleotide targeting the regulatory subunit alpha of type I protein kinase A, which plays an important role in growth and maintenance of malignancies. Preclinically, GEM231 inhibited human cancer xenografts either alone or synergistically with chemotherapeutic agents and has demonstrated an improved metabolic stability and safety profile compared to the first-generation compounds. Objectives of this study were to define the safety profile and pharmacokinetics of GEM231 administered as 2-h IV infusions twice weekly in patients with refractory solid tumors. Fourteen patients (13 evaluable for safety) received escalating doses of GEM231 at 20-360 mg/m2 (2.5-9 mg/kg). Tumor histologies included non-small cell lung cancer, renal cell cancer, sarcoma, and others. The plasma pharmacokinetics of GEM231 were linear and predictable. Maximum plasma concentration (Cmax) reached 50-70 microg/ml (8-13 microM) at dose 360 mg/m2 and 27-32 microg/ml at dose 240 mg/m2. The plasma half-life was about 1.5 h. The only clinical toxicities were transient grade I-II fever and fatigue at doses > or = 240 mg/m2. There was no treatment-related complement activation or thrombocytopenia at any dose level, except with the first dose in one patient who had pre-existing borderline thrombocytopenia. Transient activated partial thrombin time prolongation occurred at doses > or =160 mg/m2. Dose-limiting toxicities included transient activated partial thrombin time prolongation (one of three patients at 360 mg/m2) and cumulative reversible transaminase elevation (three of three patients at 360 mg/m2 and three of six patients at 240 mg/m2 during weeks 3-10). One patient with colon cancer had stabilization of a previously rising carcinoembryonic antigen. Thus, in this first clinical evaluation of a mixed-backbone oligonucleotide in cancer patients, high plasma concentrations of GEM231 were well tolerated without significant acute toxicities, but prolonged treatment was associated with reversible transaminitis. Although 240 mg/m2 by 2-h infusion twice weekly was safe for a 4-week treatment duration, alternative dosing schedules are being tested to minimize the cumulative toxicity, which will be essential to extend the duration of therapy at the highest GEM231 dose tested.  (+info)

8-chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo. (7/164)

OBJECTIVES: The aims of the present study were to assess 1) the effect of 8-C1-cAMP (cyclic-3'-5'-adenosine monophosphate) on vascular smooth muscle cell (VSMC) proliferation in vitro and 2) the efficacy of systemic administration of 8-C1-cAMP on neointimal formation after balloon injury in vivo. BACKGROUND: Neointimal formation after vascular injury is responsible for restenosis after arterial stenting. Recently, 8-C1-cAMP, a cAMP analogue that induces growth arrest, has been safely administered in phase I studies in humans. METHODS: The effect of 8-C1-cAMP on cell proliferation was first assessed on SMCs in vitro. To study the effects of cAMP in vivo, balloon injury was performed in 67 rats using a 2F Fogarty balloon catheter. RESULTS: The 8-C1-cAMP markedly inhibited VSMC proliferation in vitro, reduced protein kinase A (PKA) RIalpha subunit expression, and induced PKA RIIbeta subunit expression. In addition, 8-C1-cAMP reduced, in a dose-dependent manner, neointimal area and neointima/media ratio after balloon injury. The proliferative activity, assessed by proliferating nuclear cell antigen immunostaining, revealed a reduction of proliferative activity of VSMCs in vivo in the 8-C1-cAMP group. Moreover, the systemic administration of 8-C1-cAMP did not affect renal function, blood pressure and heart rate. CONCLUSIONS: We conclude that 8-C1-cAMP potently inhibits VSMC proliferation in vitro and reduces neointima formation by balloon injury in vivo after systemic administration. These data may have a clinical relevance in designing future strategies to prevent restenosis after arterial stenting and perhaps after percutaneous transluminal coronary angioplasty.  (+info)

Alternative 5'-exons of the mouse cAMP-dependent protein kinase subunit RIalpha gene are conserved and expressed in both a ubiquitous and tissue-restricted fashion. (8/164)

The activity of cAMP-dependent protein kinase is controlled by its regulatory subunits. Mouse RIalpha regulatory subunit expression is initiated from five different non-coding 5'-regions (exons 1a, 1b, 1c, 1d and 1e). This organization appears to be conserved among species. All mouse tissues accumulate exon 1a and 1b transcripts and most contain more 1b than 1a, except brain, heart and oesophagus. Exon 1d and 1e transcripts are found in several tissues, while exon 1c is testis-specific. All five transcripts are in RIalpha-rich tissues: gonads and adrenal glands.  (+info)

We report two interesting cases of CS in a pair of adolescent age-group brothers, due to ACTH-independent PPNAD, as a part of the CC. PPNAD is the most common cause of CS in the adolescent age group, with > 50% of the cases having CC, characterised by a mutation in PRKAR1A (protein kinase type 1-alpha regulatory subunit) [2]. Although genetic testing could not be done, both the patients fulfilled the clinical criteria for CC; the two major criteria which were satisfied were - the presence of spotty skin pigmentation, and PPNAD, while the presence of positive family history in a first-degree relative fulfilled the supplemental criteria [3]. Both the cases exhibited certain peculiarities typical of PPNAD, while few features were atypical. Both of them had a florid clinical presentation with severe stunting and various features of protein catabolism, whereas PPNAD is usually associated with a milder presentation. This could probably be attributed to the long duration of the cortisol burden in both ...
PRKAR2A_ENST00000296446 Gene, Drug Resistance, Tissue Distribution, Mutation Distribution, Variants, PRKAR2A_ENST00000296446 Genome Browser, PRKAR2A_ENST00000296446 References
Plasmid pDONR223-PRKAR1B from Dr. William Hahns lab contains the insert PRKAR1B and is published in Nature. 2010 Nov 24. ():. This plasmid is available through Addgene.
For many industries, CNC machined parts are a common requirement for their manufacturing process. Runsom Precision Co.,Ltd is well known in the industry for their high precision CNC machining capabilities for the mass production of small components required for manufacturing various products. The company ensures a speedy delivery of these CNC machined parts for industries to continue their manufacturing process without any hindrance.. According to the company spokesperson, they can supply CNC machining parts within 48 hours of receiving orders from the client. With their advanced machining equipment and a streamlined machining process, they have the ability to produce CNC machining components in bulk for their industrial clients. The company also enjoys a well-established supply chain network to ensure a speedy delivery of the processed machining parts to their clients in different parts of the world.. The spokesperson reveals that they offer an impeccable CNC machining service to supply ...
Sara Carmo Silva, Clévio Nóbrega, Marisa Ferreira-Marques, Mariana Botelho, Célia A. Aveleira, Cláudia Cavadas (Neuroendrocrinology and Aging Group, CNC) and Luís Pereira de Almeida (Vectos and Gene Therapy, CNC) in collaboration with Clévio Nóbrega (CBMR - Centre for Bio-Medical Research, UAlg ...
Designed for use with small to mid-sized automated cutting machines, this versatile, easy-to-use CNC offers advanced capabilities across a wide range of applications.
Primary pigmented nodular adrenocortical disease is a rare cause of adrenocorticotropic hormone-independent Cushings syndrome. We report an uncommon primary pigmented nodular adrenocortical disease case presenting with a unilateral adrenocortical nodule and provide a brief overview of the existing literature. A 27-year-old Caucasian woman was admitted to our Department with adrenocorticotropic hormone-independent Cushings syndrome. Its cause was initially considered a left adrenocortical adenoma based on computer tomography imaging. The patient underwent left laparoscopic adrenalectomy and histological examination revealed pigmented micronodular adrenal hyperplasia. Evaluation for the presence of Carney complex was negative. Six months later recurrence of hypercortisolism was documented and a right laparoscopic adrenalectomy was performed further establishing the diagnosis of primary pigmented nodular adrenocortical disease. After a nine-year follow-up there is no evidence of residual disease. Even
Primary pigmented nodular adrenocortical disease (PPNAD) is a pituitary-independent, primary adrenal form of hypercortisolism characterized by (a) resistance to suppression by dexamethasone and abolition of the normal diurnal rhythm of cortisol secretion, and (b) distinctive, bilateral, histopathologic changes of the adrenal glands, such as the formation of variably sized, pigmented nodular adenomas, loss of normal zonation and atrophy of the extranodular cortex. PPNAD can be associated with a variety of other manifestations, such as myxomas of the skin, heart, breast and other sites, psammomatous melanotic swannomas involving the peripheral nervous system (PNS), lentigines and blue nevi of the skin and mucosae, growth hormone (GH)-producing adenomas of the pituitary, testicular Sertoli cell tumors, and possibly other neoplasms (adrenocortical and thyroid follicular carcinoma, and ovarian cysts). These associations constitute a distinct clinical syndrome, Carney complex, a genetic syndrome. At ...
Primary pigmented nodular adrenocortical disease (PPNAD) is a pituitary-independent, primary adrenal form of hypercortisolism characterized by (a) resistance to suppression by dexamethasone and abolition of the normal diurnal rhythm of cortisol secretion, and (b) distinctive, bilateral, histopathologic changes of the adrenal glands, such as the formation of variably sized, pigmented nodular adenomas, loss of normal zonation and atrophy of the extranodular cortex. PPNAD can be associated with a variety of other manifestations, such as myxomas of the skin, heart, breast and other sites, psammomatous melanotic swannomas involving the peripheral nervous system (PNS), lentigines and blue nevi of the skin and mucosae, growth hormone (GH)-producing adenomas of the pituitary, testicular Sertoli cell tumors, and possibly other neoplasms (adrenocortical and thyroid follicular carcinoma, and ovarian cysts). These associations constitute a distinct clinical syndrome, Carney complex, a genetic syndrome. At ...
Carney complex (CNC) is a rare multiple neoplasia syndrome characterized by spotty pigmentation of the skin and mucosa in association with various non-endocrine and endocrine tumors, including primary pigmented nodular adrenocortical disease (PPNAD). A 20-year-old woman was referred for suspected Cushing syndrome. She had signs of cortisol excess as well as skin lentigines on physical examination. Biochemical investigation was suggestive of corticotropin (ACTH)-independent Cushing syndrome. Unenhanced computed tomography scan of the abdomen did not reveal an obvious adrenal mass. She subsequently underwent bilateral laparoscopic adrenalectomy, and histopathology was consistent with PPNAD. Genetic testing revealed a novel frameshift pathogenic variant c.488delC/p.Thr163MetfsX2 (ClinVar Variation ID: 424516) in the PRKAR1A gene, consistent with clinical suspicion for CNC. Evaluation for other clinical features of the complex was unrevealing. We present a case of PPNAD-associated Cushing syndrome ...
Carney complex (CNC) is a rare multiple neoplasia syndrome characterized by spotty pigmentation of the skin and mucosa in association with various non-endocrine and endocrine tumors, including primary pigmented nodular adrenocortical disease (PPNAD). A 20-year-old woman was referred for suspected Cushing syndrome. She had signs of cortisol excess as well as skin lentigines on physical examination. Biochemical investigation was suggestive of corticotropin (ACTH)-independent Cushing syndrome. Unenhanced computed tomography scan of the abdomen did not reveal an obvious adrenal mass. She subsequently underwent bilateral laparoscopic adrenalectomy, and histopathology was consistent with PPNAD. Genetic testing revealed a novel frameshift pathogenic variant c.488delC/p.Thr163MetfsX2 (ClinVar Variation ID: 424516) in the PRKAR1A gene, consistent with clinical suspicion for CNC. Evaluation for other clinical features of the complex was unrevealing. We present a case of PPNAD-associated Cushing syndrome ...
Genetic variants in components of the protein kinase A (PKA) enzyme have been associated with various defects and neoplasms in the context of Carney complex (CNC) and in isolated cases, such as in primary pigmented nodular adrenocortical disease (PPNAD), cortisol-producing adrenal adenomas (CPAs), and various cancers. PRKAR1A mutations have been found in subjects with impaired cAMP-dependent signaling and skeletal defects; bone tumors also develop in both humans and mice with PKA abnormalities. We studied the PRKACB gene in 148 subjects with PPNAD and related disorders, who did not have other PKA-related defects and identified two subjects with possibly pathogenic PRKACB gene variants and unusual bone and endocrine phenotypes. The first presented with bone and other abnormalities and carried a de novo c.858_860GAA (p.K286del) variant. The second subject carried the c.899C,T (p.T300M or p.T347M in another isoform) variant and had a PPNAD-like phenotype. Both variants are highly conserved in the ...
specificalPrinciple of the assay: PRKAR1A ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-PRKAR1A antibody and an PRKAR1A-HRP conjugate. The assay sample and buffer are incubated together with PRKAR1A-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the PRKAR1A concentration since PRKAR1A from samples and PRKAR1A-HRP conjugate compete for the anti-PRKAR1A antibody binding site. Since the number of sites is limited, as more sites are occupied by PRKAR1A from the sample, fewer sites are left to bind ...
Antisens Protein of HTLV-2 (APH-2) was described in 2009. APH-2 mRNA is expressed in vivo in most HTLV-2 carriers. In recent years, several laboratories have searched for similarities and/or differences between APH-2 and the antisens protein of HTLV-1, HBZ. Similarly to HBZ, APH-2 negatively regulates HTLV-2 transcription. However, it does not promote cell proliferation. In vivo, APH-2 localizes in discrete nuclear domains distinct from nucleoli. We therefore characterized APH-2 subcellular localization, in order to decipher the determinants of such localization and to correlate it or not with APH-2 functions. We first identify APH-2-containing nuclear domains as PML nuclear bodies (PML-NB). PML-NB are modulators of a number of cellular processes ranging from transcription regulation to cell proliferation and death. We show that both an in silico-identified nuclear localization signal and the carboxy-terminal LXXLL motif contribute to APH-2 targeting to PML-NB. Covalent modification of APH-2 by ...
Expression of PRKAR2B (PRKAR2) in cancer tissue. The cancer tissue page shows antibody staining of the protein in 20 different cancers.
CNC Routers - CNC Plasma Cutters - CNC Manufacturer - CNC Tooling - CNC Router Machines. Techno CNC Systems sells CNC Routers, CNC Plasma cutters and CNC Equipment. We focus on manufacturing new CNC routers or used CNC router machines for all production types. We manufacture CNC Routers for wood, CNC routers for plastics, CNC routers for metals and CNC routers for cabinetry. We offer affordable and quality CNC routers for woodworking shops, cabinet shops, theatres, general fabrication, sign shops and more.
Tapping the Translation Potential of cAMP-Signalling and Amyloid Inhibition using NMR. Abstract. Our work focuses on the use of NMR spectroscopy to understand two fundamental processes in humans: intracellular cAMP-dependent conformational switches and extracellular amyloid inhibition by plasma proteins. Eukaryotic cAMP-binding domains (CBDs) control multiple cellular functions (e.g. phosphorylation by protein kinase A - PKA, guanine exchange by the exchange protein directly activated by cAMP - EPAC, and ion channel gating in the hyperpolarization and cyclic-nucleotide modulated ion channels - HCN). Hence, the translational potential arising from the manipulation of cAMP-dependent signaling pathways is high. However, the ubiquity of eukaryotic CBDs also poses a challenge in terms of selectivity. Before the full translational potential of cAMP-signalling can be tapped, it is critical to understand the structural basis for selective cAMP agonism and antagonism, which is being deciphered through ...
Angry Gun CNC Adjustable Competitive Trigger Box for WE M4 GBB ( Black Trigger ) -CNC trigger box-Adjustable trigger sensitivity-Flat trigger-Weight: 115g
The spotty skin pigmentation and lentigines occur most commonly on the face, especially on the lips, eyelids, conjunctiva and oral mucosa.[3] Cardiac myxomas may lead to embolic strokes and heart failure[4] and may present with fever, joint pain, shortness of breath, diastolic rumble and tumor plop. Myxomas may also occur outside the heart, usually in the skin and breast. Endocrine tumors may manifest as disorders such as Cushing syndrome. The most common endocrine gland manifestation is an ACTH-independent Cushings syndrome due to primary pigmented nodular adrenocortical disease (PPNAD). The LAMB acronym refers to lentigines, atrial myxomas, and blue nevi.[1] NAME refers to nevi, atrial myxoma, myxoid neurofibromas, and ephelides.[1] Testicular cancer, particularly Sertoli cell type, is associated with Carney syndrome.[5] Thyroid and pancreas cancer may also occur.[6][7] Although J Aidan Carney also described Carneys triad it is entirely different.[8] ...
TY - JOUR. T1 - Operative management of Cushing Syndrome secondary to micronodular adrenal hyperplasia. AU - Powell, Anathea C.. AU - Stratakis, Constantine A.. AU - Patronas, Nicholas J.. AU - Steinberg, Seth M.. AU - Batista, Dalia. AU - Alexander, H. Richard. AU - Pingpank, James F.. AU - Keil, Meg. AU - Bartlett, David L.. AU - Libutti, Steven K.. PY - 2008/6/1. Y1 - 2008/6/1. N2 - Background: We reviewed our experience with micronodular adrenal hyperplasia (MAH), its pigmented variant primary pigmented nodular adrenocortical disease (PPNAD), and the association with Carneys complex (CNC) to better characterize these disorders. Methods: This retrospective study analyzes clinical data and operative reports of 34 patients identified with MAH and/or PPNAD who underwent resection between 1969 and 2006 at the Clinical Research Center, an inpatient research hospital at the National Institutes of Health. Symptoms and anthropometric and biochemical data were used to evaluate effect of resection. ...
Introduction: We present a rare variety of adrenocorticotrophic hormone (ACTH)-independent Cushings syndrome known as primary pigmented nodular adrenocortical disease (PPNAD). Clinical Picture: The patient initially underwent unilateral adrenalectomy for what was thought to be a left adrenal adenoma. Outcome: Partial resolution of symptoms and demonstrable persistent hypercortisolism after surgery prompted further evaluation with findings leading to the diagnosis of Carney complex. A review of the adrenal histology was consistent with PPNAD. Conclusion: This entity of PPNAD, which has rarely been reported in Asians, forms part of the Carney complex. The diagnosis may not be simple and straightforward, as illustrated in this patient ...
Pituitary tumours occur with increased frequency among patients with CNC.8PRKAR1A, the gene mutated in almost half of the patients with CNC,1,2 codes for the most abundant regulatory subunit of cAMP dependent PKA, a cellular system highly involved in pituitary cell growth and function.13,15,16 In the present study, we investigated the hypothesis that LOH or alterations of PRKAR1As sequence are involved in sporadic pituitary tumours, as well as inherited, non-CNC related pituitary tumours. The results of the experiments described here suggested that the RI-α subunit of PKA is not a significant contributor to tumorigenesis in pituitary cells, as shown by infrequent LOH of the PRKAR1A 17q22-24 locus and lack of PRKAR1A mutations in a large international series of pituitary tumours. Although the number of families that was investigated was small, we may also conclude from this study that PRKAR1A mutations are not responsible for a significant number of non-CNC related inherited pituitary lesions. ...
Learn more about Adrenocortical Disease in ferrets in this informative article from The Center for Bird and Exotic Medicine in Bothell, WA.
Background: Histiocytic sarcoma (HS) is an aggressive hematological neoplasm that responds poorly to therapy. The molecular etiology and pathology of this disease remain unclear, hampering the development of an effective therapy. Therefore, a need for more, and more realistic, animal models remains. Lymphoproliferative disorders have been reported in mice deficient for the prkar1a gene coding for the regulatory subunit type 1A of protein kinase A (PKA), but nothing is known about the role of type II PKA regulatory subunits in hematologic malignancies.. Methods: Mice deficient for the Prkar1a and Prkar2a alleles were previously reported (Kirschner et al, 2005 και Burton et al, 1997) and were kept on a mixed genetic background (C57BL/129Sv). Mice were crossed to create prkar2a+/- and prkar2a-/-. Mice were phenotyped at the ages of 3-6-9-12-18 months or when they exhibited signs of advanced disease. Tissues were collected for histological and molecular analysis.. Results: Unexpectedly, mice ...
Rabbit polyclonal antibody raised against a full-length human PRKAR1B protein. PRKAR1B (NP_002726.1, 1 a.a. ~ 381 a.a) full-length human protein. (H00005575-D01P) - Products - Abnova
Reactome is pathway database which provides intuitive bioinformatics tools for the visualisation, interpretation and analysis of pathway knowledge.
There is no cure for acrodysostosis. Treatment of the condition will be based on the symptoms that are present. Physical therapy may be helpful to treat mobility or movement problems. Jaw problems or disorders may be treated with orthodontic supports. Braces can be used to correct misaligned teeth. Surgery may be recommended in some cases for correcting bone or jaw problems.. Children with mental retardation or learning disabilities may benefit from services that help them to reach their full potential. Services can include:. ...
PIK3C2B (phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta), Authors: Dessen P. Published in: Atlas Genet Cytogenet Oncol Haematol.
View Notes - Bacterial Recombination from MCB 2000 at University of Florida. BACTERIAL RECOMBINATION Purposes A. Vaccine production (subunit type) B. Production of proteins (growth hormone) C.
The worlds first wiki where authorship really matters. Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts.
DGIdb, The Drug Gene Interaction Database, is a research resource that can be used to search candidate genes or drugs against the known and potentially druggable genome.
PTJ Prototype has been specialized in OEM 5 axis CNC lathing, custom CNC machining parts production and rapid CNC machining services China for over 13 years and always maintaining the highest standard in delivery speed and reliable quality of precision CNC manufacturing components.
New type hot sale 1325 4 axis 3d wood cnc router machine for door cabinet furniture aluminum makingng This machine with three spindle auto tool change. 2. You will be able to use the wood cnc router machine immediately. 3. You will be able to get free training advice towards our wood cnc router in our factory. Shanghai Aluson Aluminum Plastic Technology Co., Ltd
C-CNC published a new build: I am currently 14 years old, from Germany and try to build a CNC router. I only designed this CNC based on other CNC...
CNC Cutting Machine For Angle Bar CNC cutting machine for angle bar is used for notching corner of angle steel in the angle tower industry The notching die is rectangular double edge blade with multi directional rotary Only to adjust the rotating die to do the notching work so that it is not need to change ...
Colorado Springs-based Diversified Machine Systems (DMS), manufacturer of 3 Axis CNC, 5 Axis CNC and Large Format Machine Centres is proud to announce that Renishaw probing integration is now offered...
CNC BAND SAW MACHINE - SDJ 1200 cutting parts according to CNC programming on drawings, cutting with extremely fast speed, high precision, ...
This course will cover basic programming techniques, setup, operation and maintenance of CNC woodworking routers. Basic manual code creation, controller manipulation, maintenance, tooling, machine orientation and hands on part manufacturing will be presented. Specific parts will be programmed and machined.
Note: Prior to January, 2005, Redhat version 2.xx was installed. From January, 2005 to September, 2009, Debian version 4.xx was installed. Starting in October, 2009 Ubuntu version was installed. Our 6.0 version of Ubuntu with Lucid build installed starting February, 2010. Debian wheezy 2017. Current software as of 2018 is Ubuntu 12.04 with Linux CNC 2.6.11 ...
SolidCAM 2019 InventorCAM 2019 SolidCAM Car wheels CNC Machining 5 Axis ------------------------------------------------ Cung c?p b?n quy?n ph?n m?m SolidCAM & InventorCAM ?ào t?o ph?n m?m SolidCAM & ...
高い抗原親和性、特異性と安定した品質を兼ね備えたアブカムのウサギ・モノクローナル抗体 RabMAb® ab75993 交差種: Ms,Rat,Hu 適用: WB,IP,IHC-P,Flow Cyt,ICC/IF
Carney complex and its subsets LAMB syndrome and NAME syndrome are autosomal dominant conditions comprising myxomas of the heart and skin, hyperpigmentation of the skin (lentiginosis), and endocrine overactivity. It is distinct from Carneys triad. Approximately 7% of all cardiac myxomas are associated with Carney complex. The spotty skin pigmentation and lentigines occur most commonly on the face, especially on the lips, eyelids, conjunctiva and oral mucosa. Cardiac myxomas may lead to embolic strokes and heart failure and may present with fever, joint pain, shortness of breath, diastolic rumble and tumor plop. Myxomas may also occur outside the heart, usually in the skin and breast. Endocrine tumors may manifest as disorders such as Cushing syndrome. The most common endocrine gland manifestation is an ACTH-independent Cushings syndrome due to primary pigmented nodular adrenocortical disease (PPNAD). The LAMB acronym refers to lentigines, atrial myxomas, and blue nevi. NAME refers to nevi, ...
A 60 year-old male was referred for treatment of a cardiac myxoma in the right atrium. He had a past history of left atrial cardiac myxoma at age 49 and pituitary microadenoma related to acromegaly at age 55. He did not have a family history of cardiac neoplasm or endocrinopathy. The intracardiac tumor was resected and its pathology was compatible with myxoma. A diagnosis of Carney complex (CNC) was made because the diagnostic criteria of this neoplastic syndrome were satisfied by the presence of recurrent cardiac myxoma, endocrine tumor and spotty skin pigmentation. In genetic analysis novel frame shift mutation was detected in exon 2 in a heterozygous fashion in the causative gene of CNC, protein kinase A regulatory subunit 1 α (PRKAR1A). This genetic mutation is thought to cause haplo-insufficiency of PRKAR1A resulting in tumorigenesis. Although it is the most common, usually benign, cardiac tumor, myxoma can cause a critical clinical situation and thus detecting the PRKAR1A mutation can ...
Assessment of cytologic evaluation of preputial epithelial cells as a diagnostic test for detection of adrenocortical disease in castrated ferrets
London E, Nesterova M, Sinaii N, Szarek E, Chanturiya T, Mastroyannis SA, Gavrilova O, Stratakis CA: Differentially regulated protein kinase A (PKA) activity in adipose tissue and liver is associated with resistance to diet-induced obesity and glucose intolerance in mice that lack PKA regulatory subunit type IIα. Endocrinology; 2014 Sep;155(9):3397-408 ...
London E, Nesterova M, Sinaii N, Szarek E, Chanturiya T, Mastroyannis SA, Gavrilova O, Stratakis CA: Differentially regulated protein kinase A (PKA) activity in adipose tissue and liver is associated with resistance to diet-induced obesity and glucose intolerance in mice that lack PKA regulatory subunit type IIα. Endocrinology; 2014 Sep;155(9):3397-408 ...
Most PRKAR1A tumorigenic mutations lead to nonsense mRNA that is decayed; tumor formation has been associated with an increase in type II protein kinase A (PKA) subunits. The IVS6+1G>T PRKAR1A mutation leads to a protein lacking exon 6 sequences [R1 alpha Delta 184-236 (R1 alpha Delta 6)]. We compared in vitro R1 alpha Delta 6 with wild-type (wt) R1 alpha. We assessed PKA activity and subunit expression, phosphorylation of target molecules, and properties of wt-R1 alpha and mutant (mt) R1 alpha; we observed by confocal microscopy R1 alpha tagged with green fluorescent protein and its interactions with Cerulean-tagged catalytic subunit (C alpha). Introduction of the R1 alpha Delta 6 led to aberrant cellular morphology and higher PKA activity but no increase in type II PKA subunits. There was diffuse, cytoplasmic localization of R1 alpha protein in wt-R1 alpha- and R1 alpha Delta 6-transfected cells but the former also exhibited discrete aggregates of R1 alpha that bound C alpha; these were absent ...
CNC Plastic Parts CNC Machining Product Made in China, Find details about China Machining, CNC Machining from CNC Plastic Parts CNC Machining Product Made in China - Holy Precision Manufacturing Co., Limited
China Customized 2D & 3D Rotary CNC Router Machine, Find details about China CNC Router, CNC Router Machine from Customized 2D & 3D Rotary CNC Router Machine - Jinan Guanjiahong CNC Machinery Co., Ltd.
Jinan Tenma Machinery Co., Ltd. production following CNC Router:Woodworking CNC Router,Marble CNC Router,Advertising CNC Router,EPS CNC Router,CNC Machining Center,etc.
China Bakelite/Phenol-Formaldehyde CNC Machining Part for Automation Machinery, Find details about China Phenol-Formaldehyde CNC Machining, Bakelite CNC Machining from Bakelite/Phenol-Formaldehyde CNC Machining Part for Automation Machinery - Changzhou KYLT Import & Export Co., Ltd.
Sargent Metal Fabrication is an industrial supplier of bearings, bp, cnc lathes, cnc mills, cnc turning, cob, grinders, knee mills, lathes, machined.
China High Precise CNC Machined & Turned Parts-OEM Metal Parts, Find details about China Machining, CNC Machining from High Precise CNC Machined & Turned Parts-OEM Metal Parts - Holy Precision Manufacturing Co., Limited
Improve your product manufacturability for CNC punching with Falcon Precisions design tips. Falcon Precision have over 25 years experience of CNC punching.
Hardinge | Gosiger provides the CNC Machine Tools industry with products and knowledge on 5-axis, VMC, HMC, CNC machining centers, lathes, grinders, and more.
What should you look for to see if your CNC plasma cutting machines consumables are worn? Find out how to tell in this post from Multicam.
Homag Group is exhibiting the product CNC Manufacturing cells at LIGNA from 22 to 26 May. 2017 in Hannover, Germany. Plan your visit to the trade fair and search for further products.
Kúpte použité STEMAC 315 CNC Plasma Cutting Machine od 7370 € ✅ Rok výroby: 2018 ✅ Poloha: IT ✅ Dražte teraz ➤ Surplex.com
A single-light, oval backed wall sconce of cast and tooled brass. Fitted with a satin clear glass trumpet shade. Shown in Silverplate.
... sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase ... "A kinase anchoring protein (AKAP) interaction and dimerization of the RIalpha and RIbeta regulatory subunits of protein kinase ... Guild BC, Strominger JL (1984). "HLA-A2 antigen phosphorylation in vitro by cyclic AMP-dependent protein kinase. Sites of ... cAMP-dependent protein kinase type I-alpha regulatory subunit is an enzyme that in humans is encoded by the PRKAR1A gene. cAMP ...
... or cyclic AMP-dependent protein kinase. 1992: Elected to the American Academy of Arts and Sciences 1996: Elected to the ... RIalpha) subunits of PKA". Science. 307 (5710): 690-6. doi:10.1126/science.1104607. PMID 15692043. S2CID 32156686. Zhang, P; ... "Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase". Science. 253 (5018): ... She is known for her research on protein kinases, particularly protein kinase A. She was elected to the Institute of Medicine ...
Here we show that SMO uses a decoy substrate sequence to physically block the active site of the cAMP-dependent protein kinase ... PKA) catalytic subunit (PKA-C) and extinguish its enzymatic activity. As a result, GLI is released from phosphorylation-induced ... which enables a G protein-coupled receptor to physically block the enzymatic activity of a major cellular kinase. ... our findings define a mode of GPCR-PKA communication that may be harnessed by a range of membrane receptors and kinases. Happ ...
Crystal structure of cAMP-dependent Protein Kinase A Regulatory Subunit I alpha in complex with dual-specific A-Kinase ... A kinase anchor proteins and the intracellular targeting of signals carried by cyclic AMP. ... Solution structure of the docking and dimerization domain of the type I alpha regulatory subunit of protein kinase A (RIalpha D ... Crystal structure of dual-specific A-kinase anchoring protein 2 in complex with cAMP-dependent protein kinase A type II alpha ...
Cyclic AMP-Dependent Protein Kinase RIalpha Subunit / Cyclic AMP-Dependent Protein Kinases / Female / Gene Silencing / Growth ... PRKAR1A, which codes for the RIalpha regulatory subunit of cyclic AMP-dependent protein kinase A (PKA) on 17q23-24, was ... Adenoma / Aged / Carney Complex / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit / Female / Gene Deletion / Germ-Line ... was to assess involvement of loss of the PRKAR1A gene encoding a type 1α regulatory subunit of cAMP-dependent protein kinase A ...
Cyclic AMP-Dependent Protein Kinase RIalpha Subunit. *Cyclic AMP-Dependent Protein Kinases ...
To guarantee signal specificity, different PKA isoforms are compartmentalised by Akinase anchoring proteins (AKAPs) into ... functional relevance of such differential localisation was underscored by the finding of mutually exclusive and AKAP-dependent ... Signalling through protein kinase A (PKA) triggers a multitude of intracellular effects in response to a variety of ... Cyclic AMP, Cyclic AMP-Dependent Protein Kinase RIIalpha Subunit, Cyclic AMP-Dependent Protein Kinase RIalpha Subunit, ...
Cyclic AMP increases the mRNA levels for the regulatory subunit (R-II51) of type II cAMP-dependent protein kinase in rat ... cyclic adenosine monophosphate-dependent protein kinases (RII beta and RI alpha) via multiple and distinct mechanisms. ... Hormonal regulation and age dependent changes in mRNA levels for regulatory subunits of cAMP-dependent protein kinases in rat ... Cellular localization and age-dependent changes in mRNA for cyclic adenosine 3',5'-monophosphate-dependent protein kinases in ...
Sen. 1, subscore: 1.00 ]: Corn cob hydrolysates , with xylose as the dominant sugar , were fermented to ethanol by recombinant Escherichia coli KO11 . When inoculum was grown on LB medium containing glucose , fermentation of the hydrolysate was completed in 163 h and ethanol yield was 0 . 50 g ethanol/g sugar . When inoculum was grown on xylose , ethanol yield dropped , but fermentation was faster ( 113 h ) . Hydrolysate containing 72 . 0 g/l xylose and supplemented with 20 . 0 g/l rice bran was readily fermented , producing 36 . 0 g/l ethanol within 70 h . Maximum ethanol concentrations were not higher for fermentations using higher cellular concentration inocula . A simulation of an industrial process integrating pentose fermentation by E coli and hexose fermentation by yeast was carried out . At the first step , E coli fermented the hydrolysate containing 85 . 0 g/l xylose , producing 40 . 0 g/l ethanol in 94 h . Bakers yeast and sucrose ( 150 . 0 g/l ) were then added to the spent ...
Cyclic AMP Dependent Protein Kinase RIalpha Subunit Cyclic-AMP-Dependent Protein Kinase RIalpha Subunit PKA RIalpha Protein ... Cyclic AMP Dependent Protein Kinase RIalpha Subunit. Cyclic-AMP-Dependent Protein Kinase RIalpha Subunit. PKA RIalpha. Protein ... Regulatory Subunit RIalpha, Cyclic AMP Dependent Protein Kinase Regulatory Subunit RIalpha, Cyclic-AMP-Dependent Protein Kinase ... RIalpha, PKA. RIalpha, Protein Kinase A. RIalpha, cAMP Protein Kinase. Regulatory Subunit RIalpha, Cyclic AMP Dependent Protein ...
Cyclic AMP-Dependent Protein Kinase RIalpha Subunit (4) * Immune Tolerance (4) * Biomarkers, Tumor (3) ... Heavily Pigmented Epithelioid Melanoma With Loss of Protein Kinase A Regulatory Subunit-α Expression. Cohen, Jarish N; Spies, ... Superficial Angiomyxomas Frequently Demonstrate Loss of Protein Kinase A Regulatory Subunit 1 Alpha Expression: ...
Cyclic AMP-Dependent Protein Kinase RIalpha Subunit / Cyclic AMP-Dependent Protein Kinases / Female / Gene Silencing / Growth ... PRKAR1A, which codes for the RIalpha regulatory subunit of cyclic AMP-dependent protein kinase A (PKA) on 17q23-24, was ... Adenoma / Aged / Carney Complex / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit / Female / Gene Deletion / Germ-Line ... was to assess involvement of loss of the PRKAR1A gene encoding a type 1α regulatory subunit of cAMP-dependent protein kinase A ...
To guarantee signal specificity, different PKA isoforms are compartmentalised by Akinase anchoring proteins (AKAPs) into ... functional relevance of such differential localisation was underscored by the finding of mutually exclusive and AKAP-dependent ... Signalling through protein kinase A (PKA) triggers a multitude of intracellular effects in response to a variety of ... Cyclic AMP, Cyclic AMP-Dependent Protein Kinase RIIalpha Subunit, Cyclic AMP-Dependent Protein Kinase RIalpha Subunit, ...
Cyclic AMP-Dependent Protein Kinase RIalpha Subunit. *Cyclic AMP-Dependent Protein Kinases ...
KINASE RIBETA SUBUNIT. HN - 2008(1998) BX - Protein Kinase A, RIalpha Subunit MH - Cyclic AMP-Dependent Protein Kinase RIbeta ... Protein Kinase A, Type I BX - Protein Kinase Type I, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase Catalytic ... Protein Kinase A, Type II BX - Protein Kinase Type II, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase RIIalpha ... HN - 2008 BX - Protein Kinase A, Catalytic Subunits MH - Cyclic AMP-Dependent Protein Kinase RIalpha Subunit UI - D054756 MN - ...
KINASE RIBETA SUBUNIT. HN - 2008(1998) BX - Protein Kinase A, RIalpha Subunit MH - Cyclic AMP-Dependent Protein Kinase RIbeta ... Protein Kinase A, Type I BX - Protein Kinase Type I, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase Catalytic ... Protein Kinase A, Type II BX - Protein Kinase Type II, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase RIIalpha ... HN - 2008 BX - Protein Kinase A, Catalytic Subunits MH - Cyclic AMP-Dependent Protein Kinase RIalpha Subunit UI - D054756 MN - ...
KINASE RIBETA SUBUNIT. HN - 2008(1998) BX - Protein Kinase A, RIalpha Subunit MH - Cyclic AMP-Dependent Protein Kinase RIbeta ... Protein Kinase A, Type I BX - Protein Kinase Type I, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase Catalytic ... Protein Kinase A, Type II BX - Protein Kinase Type II, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase RIIalpha ... HN - 2008 BX - Protein Kinase A, Catalytic Subunits MH - Cyclic AMP-Dependent Protein Kinase RIalpha Subunit UI - D054756 MN - ...
KINASE RIBETA SUBUNIT. HN - 2008(1998) BX - Protein Kinase A, RIalpha Subunit MH - Cyclic AMP-Dependent Protein Kinase RIbeta ... Protein Kinase A, Type I BX - Protein Kinase Type I, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase Catalytic ... Protein Kinase A, Type II BX - Protein Kinase Type II, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase RIIalpha ... HN - 2008 BX - Protein Kinase A, Catalytic Subunits MH - Cyclic AMP-Dependent Protein Kinase RIalpha Subunit UI - D054756 MN - ...
KINASE RIBETA SUBUNIT. HN - 2008(1998) BX - Protein Kinase A, RIalpha Subunit MH - Cyclic AMP-Dependent Protein Kinase RIbeta ... Protein Kinase A, Type I BX - Protein Kinase Type I, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase Catalytic ... Protein Kinase A, Type II BX - Protein Kinase Type II, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase RIIalpha ... HN - 2008 BX - Protein Kinase A, Catalytic Subunits MH - Cyclic AMP-Dependent Protein Kinase RIalpha Subunit UI - D054756 MN - ...
KINASE RIBETA SUBUNIT. HN - 2008(1998) BX - Protein Kinase A, RIalpha Subunit MH - Cyclic AMP-Dependent Protein Kinase RIbeta ... Protein Kinase A, Type I BX - Protein Kinase Type I, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase Catalytic ... Protein Kinase A, Type II BX - Protein Kinase Type II, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase RIIalpha ... HN - 2008 BX - Protein Kinase A, Catalytic Subunits MH - Cyclic AMP-Dependent Protein Kinase RIalpha Subunit UI - D054756 MN - ...
KINASE RIBETA SUBUNIT. HN - 2008(1998) BX - Protein Kinase A, RIalpha Subunit MH - Cyclic AMP-Dependent Protein Kinase RIbeta ... Protein Kinase A, Type I BX - Protein Kinase Type I, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase Catalytic ... Protein Kinase A, Type II BX - Protein Kinase Type II, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase RIIalpha ... HN - 2008 BX - Protein Kinase A, Catalytic Subunits MH - Cyclic AMP-Dependent Protein Kinase RIalpha Subunit UI - D054756 MN - ...
KINASE RIBETA SUBUNIT. HN - 2008(1998) BX - Protein Kinase A, RIalpha Subunit MH - Cyclic AMP-Dependent Protein Kinase RIbeta ... Protein Kinase A, Type I BX - Protein Kinase Type I, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase Catalytic ... Protein Kinase A, Type II BX - Protein Kinase Type II, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase RIIalpha ... HN - 2008 BX - Protein Kinase A, Catalytic Subunits MH - Cyclic AMP-Dependent Protein Kinase RIalpha Subunit UI - D054756 MN - ...
KINASE RIBETA SUBUNIT. HN - 2008(1998) BX - Protein Kinase A, RIalpha Subunit MH - Cyclic AMP-Dependent Protein Kinase RIbeta ... Protein Kinase A, Type I BX - Protein Kinase Type I, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase Catalytic ... Protein Kinase A, Type II BX - Protein Kinase Type II, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase RIIalpha ... HN - 2008 BX - Protein Kinase A, Catalytic Subunits MH - Cyclic AMP-Dependent Protein Kinase RIalpha Subunit UI - D054756 MN - ...
KINASE RIBETA SUBUNIT. HN - 2008(1998) BX - Protein Kinase A, RIalpha Subunit MH - Cyclic AMP-Dependent Protein Kinase RIbeta ... Protein Kinase A, Type I BX - Protein Kinase Type I, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase Catalytic ... Protein Kinase A, Type II BX - Protein Kinase Type II, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase RIIalpha ... HN - 2008 BX - Protein Kinase A, Catalytic Subunits MH - Cyclic AMP-Dependent Protein Kinase RIalpha Subunit UI - D054756 MN - ...
KINASE RIBETA SUBUNIT. HN - 2008(1998) BX - Protein Kinase A, RIalpha Subunit MH - Cyclic AMP-Dependent Protein Kinase RIbeta ... Protein Kinase A, Type I BX - Protein Kinase Type I, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase Catalytic ... Protein Kinase A, Type II BX - Protein Kinase Type II, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase RIIalpha ... HN - 2008 BX - Protein Kinase A, Catalytic Subunits MH - Cyclic AMP-Dependent Protein Kinase RIalpha Subunit UI - D054756 MN - ...
KINASE RIBETA SUBUNIT. HN - 2008(1998) BX - Protein Kinase A, RIalpha Subunit MH - Cyclic AMP-Dependent Protein Kinase RIbeta ... Protein Kinase A, Type I BX - Protein Kinase Type I, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase Catalytic ... Protein Kinase A, Type II BX - Protein Kinase Type II, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase RIIalpha ... HN - 2008 BX - Protein Kinase A, Catalytic Subunits MH - Cyclic AMP-Dependent Protein Kinase RIalpha Subunit UI - D054756 MN - ...
KINASE RIBETA SUBUNIT. HN - 2008(1998) BX - Protein Kinase A, RIalpha Subunit MH - Cyclic AMP-Dependent Protein Kinase RIbeta ... Protein Kinase A, Type I BX - Protein Kinase Type I, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase Catalytic ... Protein Kinase A, Type II BX - Protein Kinase Type II, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase RIIalpha ... HN - 2008 BX - Protein Kinase A, Catalytic Subunits MH - Cyclic AMP-Dependent Protein Kinase RIalpha Subunit UI - D054756 MN - ...
Crystal structure of cAMP-dependent Protein Kinase A Regulatory Subunit I alpha in complex with dual-specific A-Kinase ... A kinase anchor proteins and the intracellular targeting of signals carried by cyclic AMP. ... Solution structure of the docking and dimerization domain of the type I alpha regulatory subunit of protein kinase A (RIalpha D ... Crystal structure of dual-specific A-kinase anchoring protein 2 in complex with cAMP-dependent protein kinase A type II alpha ...
Here we show that SMO uses a decoy substrate sequence to physically block the active site of the cAMP-dependent protein kinase ... PKA) catalytic subunit (PKA-C) and extinguish its enzymatic activity. As a result, GLI is released from phosphorylation-induced ... which enables a G protein-coupled receptor to physically block the enzymatic activity of a major cellular kinase. ... our findings define a mode of GPCR-PKA communication that may be harnessed by a range of membrane receptors and kinases. Happ ...
Cyclic AMP increases the mRNA levels for the regulatory subunit (R-II51) of type II cAMP-dependent protein kinase in rat ... cyclic adenosine monophosphate-dependent protein kinases (RII beta and RI alpha) via multiple and distinct mechanisms. ... Hormonal regulation and age dependent changes in mRNA levels for regulatory subunits of cAMP-dependent protein kinases in rat ... Cellular localization and age-dependent changes in mRNA for cyclic adenosine 3,5-monophosphate-dependent protein kinases in ...
... protein kinase A signaling pathway. Skin lesions are the most common manifestation of Carney complex, including … ... Cyclic AMP-Dependent Protein Kinase RIalpha Subunit / genetics Actions. * Search in PubMed ... protein kinase A signaling pathway. Skin lesions are the most common manifestation of Carney complex, including lentigines, ... under the influence of protein kinase A signaling, the production of promelanogenic EDN3 and hepatocyte GF signals. Our model ...
... sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase ... The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary ...
Cyclic-AMP-Dependent Protein Kinase RIalpha Subunit Protein Kinase A, RIalpha Subunit RI alpha, cAMP Protein Kinase RIalpha, ... RIalpha, Protein Kinase A RIalpha, cAMP Protein Kinase Regulatory Subunit RIalpha, Cyclic-AMP-Dependent Protein Kinase Registry ... Cyclic AMP-Dependent Protein Kinase RIalpha Subunit [D12.776.476.563.150.125.750.625] * Cyclic AMP-Dependent Protein Kinase ... 2008; CYCLIC-AMP-DEPENDENT PROTEIN KINASE RIALPHA SUBUNIT was indexed under CYCLIC AMP-DEPENDENT PROTEIN KINASES 1998-2007. ...
Cyclic-AMP-Dependent Protein Kinase RIalpha Subunit Protein Kinase A, RIalpha Subunit RI alpha, cAMP Protein Kinase RIalpha, ... RIalpha, Protein Kinase A RIalpha, cAMP Protein Kinase Regulatory Subunit RIalpha, Cyclic-AMP-Dependent Protein Kinase Registry ... Cyclic AMP-Dependent Protein Kinase RIalpha Subunit [D12.776.476.563.150.125.750.625] * Cyclic AMP-Dependent Protein Kinase ... 2008; CYCLIC-AMP-DEPENDENT PROTEIN KINASE RIALPHA SUBUNIT was indexed under CYCLIC AMP-DEPENDENT PROTEIN KINASES 1998-2007. ...
RI{alpha}) subunits of cyclic AMP-dependent protein kinase. Mol Cell Proteomics. 2010 Oct; 9(10):2225-37. Anand GS, ... Dissecting the cAMP-inducible allosteric switch in protein kinase A RIalpha. Protein Sci. 2010 Jun; 19(6):1213-21. Sjoberg TJ, ... Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci. 2011 Feb; 36(2):65-77. Taylor SS, Kornev AP. ... Using Markov state models to develop a mechanistic understanding of protein kinase A regulatory subunit RIα activation in ...
KINASE RIBETA SUBUNIT. HN - 2008(1998) BX - Protein Kinase A, RIalpha Subunit MH - Cyclic AMP-Dependent Protein Kinase RIbeta ... Protein Kinase A, Type I BX - Protein Kinase Type I, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase Type II UI ... HN - 2008 BX - Protein Kinase A, Catalytic Subunits MH - Cyclic AMP-Dependent Protein Kinase RIalpha Subunit UI - D054756 MN - ... protein kinase A. HN - 2008(1998) BX - Protein Kinase A, RII beta Subunit MH - Cyclic AMP-Dependent Protein Kinase Type I UI - ...
N0000178690 Cyclic AMP-Dependent Protein Kinase RIalpha Subunit N0000178691 Cyclic AMP-Dependent Protein Kinase RIbeta Subunit ... Subunit N0000178693 Cyclic AMP-Dependent Protein Kinase RIIbeta Subunit N0000178794 Cyclic AMP-Dependent Protein Kinase Type I ... N0000178580 Cyclic AMP-Dependent Protein Kinase Type II N0000170598 Cyclic AMP-Dependent Protein Kinases N0000168775 Receptors ... Protein Kinase Type I N0000185712 Cyclic GMP-Dependent Protein Kinase Type II N0000170597 Cyclic GMP-Dependent Protein Kinases ...
Here we report the apo and ADP bound structures of the myristylated catalytic subunit of PKA at 2.9 and 3.5 Å resolution, ... Although ADP release is the rate limiting step in product turnover by protein kinase A, the steps and motions involved in this ... Cyclic AMP-Dependent Protein Kinases / chemistry* Actions. * Search in PubMed * Search in MeSH ... Dynamic binding of PKA regulatory subunit RI alpha. Gullingsrud J, Kim C, Taylor SS, McCammon JA. Gullingsrud J, et al. ...
KINASE RIBETA SUBUNIT. HN - 2008(1998) BX - Protein Kinase A, RIalpha Subunit MH - Cyclic AMP-Dependent Protein Kinase RIbeta ... Protein Kinase A, Type I BX - Protein Kinase Type I, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase Catalytic ... Protein Kinase A, Type II BX - Protein Kinase Type II, Cyclic AMP-Dependent MH - Cyclic AMP-Dependent Protein Kinase RIIalpha ... HN - 2008 BX - Protein Kinase A, Catalytic Subunits MH - Cyclic AMP-Dependent Protein Kinase RIalpha Subunit UI - D054756 MN - ...
As a result, the entire N-domain and the C-domain of subunit B integrated by the cAMP portion of this ligand, together tilt ... responsible for the regulation of a multitude of diverse proteins. We have determined the crystal structures of the CRP.cAMP ... However, the bulkier N6 extension of N(6)-cAMP (in R conformation) is accommodated only in subunit A with minor changes, ... whereas in subunit B, the N6 extension is in the S conformation hindering the hinge region of the central helix. ...
Using Markov state models to develop a mechanistic understanding of protein kinase A regulatory subunit RIalpha activation in ... A predictive computational model reveals that giv/girdin serves as a tunable valve for egfr-stimulated cyclic amp signals.. ... Whole-Cell Photobleaching Reveals Time-Dependent Compartmentalization of Soluble Proteins by the Axon Initial Segment.. ... Contributions of protein kinases and beta-arrestin to termination of protease-activated receptor 2 signaling. Jung, S. R., Seo ...
... protein time point with acid nos oral other quantitative concentration for gene product left antibody right tablet serum ... fire foley metal leukocytes challenge deformity ile bromo valyl plant ureter coated tests diabetes action cyclic encourage ... length normal pulmonary breast therapy abdominal vertebral name peptide collision membrane limb enzyme partial potassium kinase ... communication conditions fibrinogen genetics notch phase latex tar descending forte mdl data herpesvirus communicating foam amp ...
  • A type I cAMP-dependent protein kinase regulatory subunit that plays a role in confering CYCLIC AMP activation of protein kinase activity. (bvsalud.org)
  • The adenosine 3',5'-cyclic monophosphate (cAMP)-dependent protein kinase (PKA) is localized through interaction of the regulatory (R) subunit dimer with A-kinase-anchoring proteins (AKAPs). (embl.de)
  • P. Banky, L. Huang, and S. S. Taylor , Dimerization/docking domain of the type Ia regulatory subunit of cAMP-dependent protein kinase. (inserm.fr)
  • Here we show that SMO uses a decoy substrate sequence to physically block the active site of the cAMP-dependent protein kinase (PKA) catalytic subunit (PKA-C) and extinguish its enzymatic activity. (nature.com)
  • To guarantee signal specificity, different PKA isoforms are compartmentalised by Akinase anchoring proteins (AKAPs) into functional microdomains. (ox.ac.uk)
  • Contains dimerisation interface and binding site for A-kinase-anchoring proteins (AKAPs). (embl.de)
  • Dual specificity protein kinases (e.g. (embl.de)
  • In addition to its role as an inhibitor of the C subunit, the R subunit anchors the holoenzyme to specific intracellular locations and prevents the C subunit from entering the nucleus. (embl.de)
  • Pituitary adenomas: role of cyclin-dependent kinase inhibitors, Springer, Oct. 2013. (tokushima-u.ac.jp)
  • Identification of protease serine S1 family member 53 as a mitochondrial protein in murine islet beta cells, Islets, Vol.14, No.1, 1-13, 2021. (tokushima-u.ac.jp)
  • Signalling through protein kinase A (PKA) triggers a multitude of intracellular effects in response to a variety of extracellular stimuli. (ox.ac.uk)
  • The functional relevance of such differential localisation was underscored by the finding of mutually exclusive and AKAP-dependent increases in [cAMP] in the PKA type I and PKA type II microdomains upon application of different cAMP agonists. (ox.ac.uk)
  • We now report the solution structure of the type II PKA R-subunit fragment RIIalpha(1-44), which encompasses both the AKAP-binding and dimerization interfaces. (embl.de)
  • NMR data on the complex between RIIalpha(1-44) and an AKAP fragment reveals extensive contacts between the two proteins. (embl.de)
  • Protein kinases catalyse the transfer of the gamma phosphate from nucleotide triphosphates (often ATP) to one or more amino acid residues in a protein substrate side chain, resulting in a conformational change affecting protein function. (embl.de)
  • Phosphorylation usually results in a functional change of the target protein by changing enzyme activity, cellular location, or association with other proteins. (embl.de)
  • Protein phosphorylation, which plays a key role in most cellular activities, is a reversible process mediated by protein kinases and phosphoprotein phosphatases. (embl.de)
  • The molecular basis for protein kinase A anchoring revealed by solution NMR. (embl.de)
  • In conclusion, DDT transcription may be regulated in a cell-dependent manner, and were enhanced by AMPK activation in SGBS adipocytes through inhibiting the mTOR signaling. (tokushima-u.ac.jp)
  • A pivotal step in Hh signal transduction is the activation of glioma-associated (GLI) transcription factors by the atypical G protein-coupled receptor (GPCR) SMOOTHENED (SMO). (nature.com)
  • There are 1650 RIIa domains in 1614 proteins in SMART's nrdb database. (embl.de)
  • Formation of these complexes is mediated by specialized protein motifs that participate in protein-protein interactions. (embl.de)
  • Hui, C. C. & Angers, S. Gli proteins in development and disease. (nature.com)
  • Age-dependent development of liver fibrosis in Glmp (gt/gt) mice. (uio.no)
  • A type I cAMP-dependent protein kinase regulatory subunit that plays a role in confering CYCLIC AMP activation of protein kinase activity. (nih.gov)
  • Over fifty members of this family exist, most of which bind specifically to regulatory subunits of CYCLIC-AMP-DEPENDENT PROTEIN KINASE TYPE II such as CAMP PROTEIN KINASE RIIALPHA or CAMP PROTEIN KINASE RIIBETA. (nih.gov)
  • Molecular Simulations Reveal an Unresolved Conformation of the Type IA Protein Kinase A Regulatory Subunit and Suggest Its Role in the cAMP Regulatory Mechanism. (omicsdi.org)
  • We identify a previously unresolved, unrecognized, and highly stable conformation of the protein kinase A (PKA) regulatory subunit RI? (omicsdi.org)
  • Isoleucine 368 is involved in low-affinity binding of N6-modified cAMP analogues to site B of the regulatory subunit of cAMP-dependent protein kinase I. (omicsdi.org)
  • Corrigendum to "A Catalytically-Disabled Double Mutant of Src Tyrosine Kinase Can Be Stabilized into an Active-Like Conformation. (ucsd.edu)
  • However, the bulkier N6 extension of N(6)-cAMP (in R conformation) is accommodated only in subunit A with minor changes, whereas in subunit B, the N6 extension is in the S conformation hindering the hinge region of the central helix. (omicsdi.org)
  • Brownian dynamics simulations suggest that the Flipback conformation plays a role in cAMP association to the A domain of the R subunit. (omicsdi.org)
  • Disordered Protein Kinase Regions in Regulation of Kinase Domain Cores. (ucsd.edu)
  • The cAMP receptor protein (CRP) from Mycobacterium tuberculosis is a cAMP-responsive global transcriptional regulator, responsible for the regulation of a multitude of diverse proteins. (omicsdi.org)
  • Carney complex is a rare familial multineoplastic syndrome predisposing to endocrine and nonendocrine tumors due to inactivating mutations of PRKAR1A, leading to perturbations of the cAMP‒protein kinase A signaling pathway. (nih.gov)
  • Structural insights into the mechanism of the allosteric transitions of Mycobacterium tuberculosis cAMP receptor protein. (omicsdi.org)
  • Based on the CRP.N(6)-cAMP crystal structure, binding of N(6)-cAMP with a bulkier methylphenylethyl extension from the N6 atom stabilizes the cAMP-binding domain, N-domain hairpin, and C-terminal domain in a similar manner as that of the CRP.cAMP structure, maintaining structural integrity within the subunits. (omicsdi.org)
  • As a result, the entire N-domain and the C-domain of subunit B integrated by the cAMP portion of this ligand, together tilt away ( approximately 7 degrees tilt) from central helix C, positioning the helix-turn-helix motif in an unfavorable position for the DNA substrate, asymmetrically. (omicsdi.org)
  • Epac2 is a member of the family of exchange proteins directly activated by cAMP (Epac). (omicsdi.org)
  • HN - 2008 (1997) MH - Alpha-Amanitin UI - D053959 MN - D4.345.566.50.111 MN - D12.644.456.50.111 MN - D12.644.641.50.111 MN - D23.946.587.175.111 MS - A cyclic octapeptide with a thioether bridge between the cystine and tryptophan. (nih.gov)
  • Hypothesis: Unifying model of domain architecture for conventional and novel protein kinase C isozymes. (ucsd.edu)
  • The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGψ motif in the kinase domain. (ucsd.edu)
  • HN - 2008 (1993) MH - Agouti-Related Protein UI - D054369 MN - D12.644.276.74 MN - D12.776.467.74 MN - D23.529.74 MS - A secreted protein of approximately 131 amino acids that is related to AGOUTI SIGNALING PROTEIN and is also an antagonist of MELANOCORTIN RECEPTOR activity. (nih.gov)
  • Apo structure of the catalytic subunit of PKA. (nih.gov)
  • Structure of a B12-dependent radical SAM enzyme in carbapenem biosynthesis. (vcell.org)
  • 11/05/2007) TOTAL 2008 NEW DESCRIPTORS = 456 MH - A Kinase Anchor Proteins UI - D054758 MN - D12.644.360.24.65 MN - D12.776.157.57.01 MN - D12.776.476.24.69 MS - A structurally-diverse family of intracellular-signaling adaptor proteins that selectively tether specific protein kinase A subtypes to distinct subcellular sites. (nih.gov)